Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1439 plus Truvada versus efavirenz plus Truvada in treatment-naive HIV-1 infection
NL-OMON41652Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of doravirine in Human immunodeficiency virus infection type 1 (5 arms), sponsored by Merck & Co. Primary endpoints: Virologic response at Week 24 and Safety and tolerability through Week 24. Started May 2013; status: active, not recruiting.
02
Drugs
doravirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON41652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41652.